Mercados españoles cerrados

Acorda Therapeutics, Inc. (ACOR)

NasdaqGS - NasdaqGS Precio demorado. Divisa en USD
Añadir a la lista de favoritos
13,21+1,11 (+9,18%)
Al cierre: 04:00PM EDT
13,98 +0,77 (+5,82%)
Después del cierre: 04:41PM EDT

Acorda Therapeutics, Inc.

2 Blue Hill Plaza
3rd Floor
Pearl River, NY 10965
United States
914 347 4300
https://www.acorda.com

Sector(es)Healthcare
SectorDrug Manufacturers - Specialty & Generic
Empleados a tiempo completo111

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Dr. Ron Cohen M.D.Founder, CEO, President & Director984,15kN/A1956
Mr. Michael A. Gesser M.B.A.Chief Financial Officer459,15kN/A1963
Mr. Kerry M. ClemChief Commercial Officer592,23kN/A1970
Mr. Robert MoralesInterim Principal Accounting Officer, Principal Financial Officer, VP of Finance & ControllerN/AN/A1968
Ms. Felicia VonellaVice President of Investor RelationsN/AN/AN/A
Mr. Neil S. Belloff Esq.General Counsel & Corporate SecretaryN/AN/A1960
Ms. Tierney SaccavinoExecutive Vice President of Corporate CommunicationsN/AN/AN/A
Ms. Denise J. DucaExecutive Vice President of Human ResourcesN/AN/AN/A
Mr. Andrew Mayer J.D.Senior Vice PresidentN/AN/AN/A
Sofia AliSenior VP of Operations & Strategic PlanningN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

Gobierno corporativo

El ISS Governance QualityScore de Acorda Therapeutics, Inc., a día 1 de marzo de 2024, es 7. Las puntuaciones base son Auditoría: 8; Tablero: 5; Derechos de los accionistas: 7; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.